Definition of advanced age in HIV infection: Looking for an age cut-off

AIDS Research and Human Retroviruses

Volumn 28, Issue 9, 2012, Pages 800-806

  Blanco, José R ^a   Jarrín, Inmaculada ^b   Vallejo, Manuel ^a   Berenguer, Juan ^c   Solera, Carmen ^d   Rubio, Rafael ^e   Pulido, Federico ^e   Asensi, Victor ^f   Del Amo, Julia ^b   Moreno, Santiago ^g  

^a HOSPITAL SAN PEDRO   (Spain)

^b CARLOS III INSTITUTE OF HEALTH   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; AGE; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; SURVIVAL; VIRUS LOAD;

EID: 84865448968     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0377     Document Type: Article

References (54)

1. Bhavan KP, Kampalath VN, and Overton ET: The aging of the HIV epidemic. Curr HIV/AIDS Rep 2008;5:150-158.
2. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, et al. Aging and infectious diseases: Workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008;47:542-553.
3. Deeks SG and Phillips AN: HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009;338:288-292.
4. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
5. Knobel H, Guelar A, Valldecillo G, Carmona A, González A, López-Colomés JL, et al. Response to highly active antiretroviral therapy in HIV-1 infected patients aged 60 years or older after 24 months of follow up. AIDS 2001;15:1591-1593. (Pubitemid 32744614)
6. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: Evidence from the EuroSIDA study. J Infect Dis 2001;183:1290-1294. (Pubitemid 32281572)
7. Yamashita TE, Phair JP, Muñoz A, Margolick JB, Detels R, O'Brien SJ, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001;15:735-746. (Pubitemid 32423221)
8. Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004;18:2029-2038.
9. Goodkin K, Shapshak P, Asthana D, Zheng W, Concha M, Wilkie FL, et al. Older age and plasma viral load in HIV-1 infection. AIDS 2004;18(Suppl 1):S87-98. (Pubitemid 38365911)
10. Kalayjian RC, Spritzler J, Pu M, Landay A, Pollard R, Stocker V, et al. Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis 2005;192:1577-1587. (Pubitemid 41504693)
11. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al.: Characteristics, determinants, and clinical relevance of CD4 T cell recovery to Y 500 cells/microLin HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005;41:361-372. (Pubitemid 41022115)
12. Manfredi R and Chiodo F: A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS 2000;14:1475-1477. (Pubitemid 30459534)
13. Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP, et al. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008;48:541-546.
14. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group: Response to combination antiretroviral therapy: variation by age. AIDS 2008;22:1463-1473.
15. Nogueras MM, Navarro G, Antón E, Sala M, Cervantes M, Amengual MJ, et al. Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more. BMC Infect Dis 2006;6:159.
16. Perez JL and Moore RD: Greater effect of highly active antiretroviral therapy on survival in people aged > or = 50 years compared with younger people in an urban observational cohort. Clin Infect Dis 2003;36:212-218. (Pubitemid 36143421)
17. Vallecillo G, Knobel H, Guelar A, and Saballs P: Evolución de una cohorte de pacientes mayores de 60 años infectados por el VIH tratados con tratamiento antirretroviral de gran actividad. Enferm Infecc Microbiol Clin 2005;23:390-391. (Pubitemid 41020556)
18. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, and Quesenberry CP Jr: Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007;167:684-691. (Pubitemid 46598461)
19. Navarro G, Nogueras MM, Segura F, Casabona J, Miró JM, Murillas J, et al. HIV-1 infected patients older than 50 years. PISCIS cohort study. J Infect 2008;57:64-71.
20. Clinical management and treatment of HIV infected adults in Europe. Available at http://www.europeanaidsclinicalsociety.org/guidelinespdf/1- Treatment-of-HIV-Infected-Adults.pdf. Accesed December 11, 2010.
21. Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antiretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero de 2012). Available at http://www.gesida-seimc.org/pcientifica/fuentes/DcyRc/gesidad cyrc2012-Documentoconsenso-TAR-adulto-verordenador.pdf. Accessed May 18, 2012.
22. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010;304:321-333.
23. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents-March 27, 2012. Available at http://www.aidsinfo.nih.gov/ Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search= Off&GuidelineID=7&ClassID=1. Accessed May 18, 2012.
24. Garcia-Merino I, de Las CN, Jimenez JL, Gallego J, Gomez C, Prieto C, et al. The Spanish HIV BioBank: A model of cooperative HIV research. Retrovirology 2009;6:27.
25. Caro-Murillo AM, Castilla J, Pérez-Hoyos S, Miró JM, Podzamczer D, Rubio R, et al. Cohorte RIS de pacientes con infección por VIH sin tratamiento antirretroviral previo (CoRIS): Metodología y primeros resultados. Enferm Infecc Microbiol Clin 2007;25:23-31. (Pubitemid 46232687)
26. Battegay M, Nuesch R, Hirschel B, and Kaufmann GR: Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006;6:280-287.
27. Grimes RM, Otiniano ME, Rodriguez-Barradas MC, and Lai D: Clinical experience with human immunodeficiency virusinfected older patients in the era of effective antiretroviral therapy. Clin Infect Dis 2002;34:1530-1533. (Pubitemid 34553714)
28. Manfredi R, Calza L, Cocchi D, and Chiodo F: Antiretroviral treatment and advanced age: Epidemiologic, laboratory, and clinical features in the elderly. J Acquir Immune Defic Syndr 2003;33:112-114. (Pubitemid 36547249)
29. Tumbarello M, Rabagliati R, de Gaetano DK, Bertagnolio S, Tamburrini E, Tacconelli E, et al. Older HIV-positive patients in the era of highly active antiretroviral therapy: changing of a scenario. AIDS 2003;17:128-131. (Pubitemid 36106310)
30. Tumbarello M, Rabagliati R, de Gaetano DK, Bertagnolio S, Montuori E, Tamburrini E, et al. Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2004; 4:46.
31. Orlando G, Meraviglia P, Cordier L, Meroni L, Landonio S, Giorgi R, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med 2006;7:549-557. (Pubitemid 44742356)
32. Cuzin L, Delpierre C, Gerard S, Massip P, and Marchou B: Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged > 50 years. Clin Infect Dis 2007;45:654-657. (Pubitemid 47328650)
33. Brañas F, Berenguer J, Sánchez-Conde M, López- Bernaldo de Quiró s JC, Miralles P, Cosín J, et al. The eldest of older adult living with HIV: response and adherence to highly active antiretroviral therapy. Am J Med 2008;121:820-824.
34. Stall R and Catania J: AIDS risk behaviors among late middle-aged and elderly Americans: The national AIDS behavioral surveys. Arch Intern Med 1994;154:57-63. (Pubitemid 24018102)
35. Antón E, Sala M, Mallolas J, Navarro G, Cervantes M, Gatell JM, et al. Estudio de una serie clínica de pacientes infectados por el VIH mayores de 50 años. Enferm Infecc Microbiol Clin 2005;23:145-148. (Pubitemid 40469409)
36. Orchi N, Balzano R, Scognamiglio P, Navarra A, De Carli G, Elia P, et al. Ageing with HIV: Newly diagnosed older adults in Italy. Aids Care 2008;20:419-425. (Pubitemid 351652489)
37. Caro-Murillo AM, Gil A, Navarro G, Leal M, Blanco JR, and CoRIS: La infección por VIH en diferentes grupos de edad: potenciales implicaciones para la prevenció n. Cohorte CoRIS, España, 2004-2008. Med Clin (Barc) 2010;134:521-527.
38. Smith RD, Delpech VC, Brown AE, and Rice BD: HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS 2010;24:2109-2115.
39. Caro-Murillo AM, Gil Luciano A, Navarro Rubio G, Leal Noval M, and Blanco Ramos JR: Infección por el virus de la inmunodeficiencia humana en diferentes grupos de edad: implicaciones potenciales para la prevenció n. Cohorte CoRIS, España, 2004-2008. Med Clin (Barc) 2010;134:521-527.
40. Greenbaum AH, Wilson LE, Keruly JC, Moore RD, and Gebo KA: Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS 2008;22:2331-2339.
41. Carrieri MP, Leport C, Protopescu C, Cassuto JP, Bouvet E, Peyramond D, et al. Factors associated with nonadherence to highly active antiretroviral therapy. A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 2006;41:477-485.
42. Barclay TR, Hinkin CH, Castellon SA, Mason KI, Reinhard MJ, Marion SD, et al. Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol 2007;26:40-49. (Pubitemid 46072023)
43. Zaragoza-Macias E, Cosco D, Nguyen ML, Del Rio C, and Lennox J: Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population. AIDS Res Hum Retroviruses 2010;26:133-138.
44. Palella FJJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era changing causes of death and disease in the HIV outpatient study. J AcquirImmune Defic Syndr 2006;43:27-34. (Pubitemid 44306484)
45. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-59. (Pubitemid 351920404)
46. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008;22:2143-2153.
47. Antiretroviral Therapy Cohort Collaboration: Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010;50:1387-1396.
48. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000;355:1131-1137.
49. Egger M, May M, Chê (Pubitemid 34786200)
50. Gutiérrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, et al. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: Longterm follow-up of a multicenter cohort. PLOS One 2008;1:e89.
51. Shah S, McGowan J, Smith S, Blum S, and Klein R: Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis 2002;35:1238-1243. (Pubitemid 35305872)
52. Braithwaite RS, Justice A.C., Chang CCH, Fusco JS, Raffanti S, Wong JB, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med 2005;118:890-898. (Pubitemid 41097468)
53. Gutiérrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, et al. Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. Curr HIV Res 2008;6:100-107. (Pubitemid 351479789)
54. Garcia F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4 + Tcell count. J Acquir Immune Defic Syndr 2004;36:702-713. (Pubitemid 38685964)